医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

A.M. Best Assigns Ratings to Health Services Welfare Society Limited

2014年05月31日 AM03:00
このエントリーをはてなブックマークに追加


 

HONG KONG

A.M. Best has assigned a financial strength rating of B (Fair) and issuer credit rating of “bb+” to Health Services Welfare Society Limited (New Zealand). The outlook assigned to both ratings is stable.

Established in 1971, Health Services Welfare Society Limited, trading as Accuro Health Insurance (Accuro), is a not-for-profit, limited liability society in New Zealand. Its principal activity is to provide sickness, accident, hospital, surgical, specialists, medical benefits and bereavement grants to its members.

The ratings reflect Accuro’s good business profile in the retail medical insurance sector of New Zealand, favorable growth and experience of its on-sale products (launched since 2010), as well as its low investment risk profile.

Partially offsetting these positive factors are the high underwriting leverage and less favorable experience of its legacy products.

Accuro’s premium earned was in excess of four time surplus, which makes capitalization very sensitive to higher-than-expected claim severity or frequency. Despite the favorable experience of its on-sale products, the company’s legacy products, which represented over half of overall premium earned, consistently reported high claim ratios.

An upgrading of the company’s ratings is unlikely in the short to medium term until it can demonstrate a solid track record of positive underwriting results. Meanwhile, any significant adverse changes to its industry environment or continued underwriting losses could lead to a downgrading of its ratings.

The methodology used in determining these interactive ratings is Best’s Credit Rating Methodology, which provides a comprehensive explanation of A.M. Best’s rating process and contains the different rating criteria employed in the rating process. Best’s Credit Rating Methodology can be found at www.ambest.com/ratings/methodology.

Ratings are communicated to rated entities prior to publication, and unless stated otherwise, the ratings were not amended subsequent to that communication.

This rating announcement has been issued by A.M. Best Asia-Pacific Limited, which is a subsidiary of A.M. Best Company. A.M. Best Company is the world’s oldest and most authoritative insurance rating and information source. For more information, visit

Copyright © 2014 by A.M. Best Company, Inc. ALL RIGHTS RESERVED.

CONTACT

A.M. Best
Jason Shum, 852-2827-3430
Financial Analyst
jason.shum@ambest.com
or
Ken
Chow, 852-2827-3426
Senior Financial Analyst
ken.chow@ambest.com
or
Jim
Peavy, 908-439-2200, ext. 5644
Assistant Vice President, Public
Relations
james.peavy@ambest.com

同じカテゴリーの記事 

  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護